期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

核因子-κB在非小细胞肺癌表皮生长因子受体-酪氨酸酶抑制剂耐药中的作用和机制

原文传递
导出
摘要 近十年来,全球范围内肺癌的发病率和病死率迅速上升,其中非小细胞肺癌（non-small cell lung cancer,NSCLC）约占80%-85%。在NSCLC的治疗中,以表皮生长因子受体（epidermal growth factor receptor,EGFR）为靶点的酪氨酸酶抑制剂（tyrosine kinase inhibitor,TKI）开创了分子靶向治疗的新时代。
作者 卞家蓉 徐兴祥
机构地区 江苏省苏北人民医院呼吸内科
出处 《中华肺部疾病杂志（电子版）》 CAS 2015年第3期85-88,共4页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家自然科学基金(81302016)
关键词 核因子-ΚB 非小细胞肺癌 表皮生长因子受体-酪氨酸酶抑制剂
分类号 R734.2 [医药卫生—肿瘤] R563 [医药卫生—呼吸系统]
  • 相关文献

参考文献40

  • 1任成山,白莉,钱桂生.慢性阻塞性肺疾病合并肺癌临床特征及新理念[J].中华肺部疾病杂志（电子版）,2015,8(2):1-5. 被引量：66
  • 2Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung2) : a phase 2 trial[J]. LancetOncol, 2012,13(5): 539-548.
  • 3Yamamoto N, Katakami N, Atagi S, et al. A phase II trial of afatinib ( BIBW 2992) in patients ( pts ) with advanced non-small cell lung cancer previously treated with erlotinib ( E) or gefitinib (G)[J]. J Clin Oncol, 2011, 29(Suppl) : a7524.
  • 4Yang J, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase m study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations[J]. J Clin Oncol, 2012, 30(Suppi) : a LBA7500.
  • 5Califano R, Landi L, Cappuzzo F. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer[J]. Drugs, 2012, 72 (Suppl 1) : 28-36.
  • 6Cadranel J, Ruppert AM, Beau-Faller M, et al. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma[J]. Crit Rev Oncol Hematol , 2013, 88 (3) : 447493.
  • 7Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-KB signalling modulate dependence of lung cancers on mutant EGFR[J]. Nature, 2011,471 (7339) : 523-526.
  • 8Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. Lancet Oncol, 2011,12(2): 175-180.
  • 9Pallis A, Briasoulis E, Linardou H, et al. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations[J]. Current Medicinal Chemistry, 2011, 18 (11) : 1613-1628.
  • 10Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers[J]. J Pathol, 2011,223(2): 219-229.

二级参考文献89

  • 1Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61(2): 69-90.
  • 2Sher T, Dy GK, Adjei AA. Small cell lung cancer[J]. Mayo Clin Proc, 2008, 83(3) : 355-367.
  • 3Horn L, Pao W. EML4-ALK: honing in on a new target in non- small-cell lung cancer [ J ]. J Clin Oncol, 2009, 27 (26) : 4232- 4235.
  • 4Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer[ J]. Nature, 2007, 448(7153) : 561-566.
  • 5Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers [ J ]. J Thorac Oncol, 2008, 3(1) : 13-17.
  • 6Perner S, Wagner P L, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event [ J ]. Neoplasia, 2008, 10 ( 3 ) : 298-302.
  • 7Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologie types of lung cancers from nonsmokers with wild-type EGFR and KRAS [ J ]. Cancer, 2009, 115(8) : 1723-1733.
  • 8Shaw AT, Yeap BY, Mino-Kenudsan M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMIA-ALK[ J]. J Clin Oneol, 2009, 27(26) : 4247-4253.
  • 9Martelli MP, Sozzi G, Hemandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues [ J ]. Am J Pathol, 2009, 174(2): 661-670.
  • 10Sasaki T, Rodig SJ, Chirieae LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer[ J]. Eur J Cancer, 2010, 46(10) : 1773-1780.

共引文献79

中华肺部疾病杂志（电子版）
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部